Article Text

Download PDFPDF
Oestrogen plus progestogen did not reduce the risk of coronary heart disease in postmenopausal women

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In postmenopausal women, how does oestrogen plus progestogen influence the risk of coronary heart disease (CHD)?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Endocrine ★★★★★☆☆ Cardiology ★★★★★☆☆


Embedded ImageDesign:

randomised placebo controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee).

Embedded ImageFollow up period:

5.6 years (Women’s Health Initiative [WHI]).

Embedded ImageSetting:

{40 US clinical centres}*.

Embedded ImagePatients:

16 608 postmenopausal women who were 50–79 years of age (mean age 63 y), had an intact uterus, and resided in the same geographic area for ⩾3 years.

Embedded ImageInterventions:

patients were allocated to oral conjugated equine oestrogen, 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n = 8506), or placebo (n = 8102).

Embedded ImageOutcomes:

CHD (ie, acute myocardial infarction [MI] requiring overnight hospital admission; death …

View Full Text


  • *

  • See glossary.

  • For correspondence: Dr J E Manson, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA.

  • Source of funding: National Heart, Lung and Blood Institute.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd